NDAINJECTIONINJECTABLE
Approved
Dec 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
COGENTIN (benztropine mesylate) by Molecular Devices is clinical pharmacology benztropine mesylate possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism. First approved in 1959.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COGENTIN (benztropine mesylate) is an injectable anticholinergic agent approved in 1959 for managing parkinsonism and drug-induced extrapyramidal reactions. It works by blocking acetylcholine activity in the central nervous system, reducing tremor and rigidity associated with Parkinson's disease and antipsychotic side effects.
LOE Approaching
As LOE approaches, brand team resources are likely consolidating; career growth may be limited unless supporting transition to generic-era support roles.
Mechanism of Action
CLINICAL PHARMACOLOGY Benztropine mesylate possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism. In the isolated guinea pig ileum, the anticholinergic activity of this drug is about…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
COGENTIN offers limited career growth potential given its approaching LOE status and minimal linked job postings. Professionals joining this team should expect role focus on product maintenance, generic transition management, and compliance rather than commercial expansion or innovation.
Brand Manager (maintenance focus)
Worked on COGENTIN at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.